Poseida Therapeutics, Inc. (PSTX) financial statements (2022 and earlier)

Company profile

Business Address 9390 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:206,300309,200
Cash and cash equivalents206,32583,966
Short-term investments 225,186
Other undisclosed cash, cash equivalents, and short-term investments(25)48
Prepaid expense4,8094,056
Other undisclosed current assets2,764740
Total current assets:213,873313,996
Noncurrent Assets
Operating lease, right-of-use asset26,17724,986
Property, plant and equipment22,05023,336
Intangible assets, net (including goodwill)5,5485,548
Goodwill4,2284,228
Intangible assets, net (excluding goodwill)1,3201,320
Other noncurrent assets1,6613,618
Total noncurrent assets:55,43657,488
TOTAL ASSETS:269,309371,484
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,2099,395
Accounts payable8,961763
Accrued liabilities2,4881,839
Employee-related liabilities8,7606,793
Deferred revenue4,497 
Other undisclosed current liabilities18,62920,630
Total current liabilities:43,33530,025
Noncurrent Liabilities
Long-term debt and lease obligation54,86154,507
Long-term debt, excluding current maturities29,35729,133
Operating lease, liability25,50425,374
Liabilities, other than long-term debt10,9101,229
Deferred revenue9,265 
Deferred income tax liabilities5555
Other liabilities1,5901,174
Other undisclosed noncurrent liabilities3,99223,755
Total noncurrent liabilities:69,76379,491
Total liabilities:113,098109,516
Stockholders' equity
Stockholders' equity attributable to parent156,211261,968
Common stock66
Additional paid in capital563,064543,842
Accumulated other comprehensive income 5
Accumulated deficit(406,859)(281,885)
Total stockholders' equity:156,211261,968
TOTAL LIABILITIES AND EQUITY:269,309371,484

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Revenues31,238 
Gross profit:31,238 
Operating expenses(172,649)(126,549)
Operating loss:(141,411)(126,549)
Nonoperating income
(Other Nonoperating income)
19,795280
Interest and debt expense(3,358)(3,506)
Net loss available to common stockholders, diluted:(124,974)(129,775)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(124,974)(129,775)
Other comprehensive loss (14)
Comprehensive loss:(124,974)(129,789)
Other undisclosed comprehensive loss, net of tax, attributable to parent(5) 
Comprehensive loss, net of tax, attributable to parent:(124,979)(129,789)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: